# Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine

> **NCT01831050** · PHASE4 · COMPLETED · sponsor: **Fidec Corporation** · enrollment: 1420 (estimated)

## Conditions studied

- Poliomyelitis

## Interventions

- **BIOLOGICAL:** Bivalent Oral Polio Vaccine (bOPV)
- **BIOLOGICAL:** Trivalent Oral Polio Vaccine (tOPV)
- **BIOLOGICAL:** Monovalent Oral Polio Vaccine Type 2 (mOPV2)
- **BIOLOGICAL:** Sanofi-Pasteur IPV (Sanofi IPV)
- **BIOLOGICAL:** Glaxo SmithKline IPV (GSK IPV)
- **BIOLOGICAL:** Serum Institute of India IPV (SII IPV)

## Key facts

- **NCT ID:** NCT01831050
- **Lead sponsor:** Fidec Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2014-04
- **Final completion:** 2014-12
- **Target enrollment:** 1420 (ESTIMATED)
- **Last updated:** 2015-08-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01831050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01831050, "Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01831050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*